These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7555203)

  • 1. Bactericidal kinetics of an in vitro infection model of once-daily ceftriaxone plus amikacin against gram-positive and gram-negative bacteria.
    Scaglione F; Dugnani S; Demartini G; Arcidiacono MM; Cocuzza CE; Fraschini F
    Chemotherapy; 1995; 41(4):239-46. PubMed ID: 7555203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of protein binding on the pharmacodynamics of ceftazidime or ceftriaxone against gram-positive and gram-negative bacteria in an in vitro infection model.
    Scaglione F; Demartini G; Arcidiacono MM; Dugnani S; Fraschini F
    J Chemother; 1998 Feb; 10(1):29-34. PubMed ID: 9531073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an
    Werth BJ; Shireman LM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer.
    Castagnola E; Lanino E; Giacchino R; Viscoli C; Dini G
    J Chemother; 1999 Feb; 11(1):54-60. PubMed ID: 10078782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic post-antibiotic effect of amikacin and beta-lactam antibiotics on Enterococcus faecalis.
    Isaksson B; Hanberger H; Maller R; Nilsson LE; Nilsson M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():9-14. PubMed ID: 1906865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
    Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
    Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ceftriaxone and amikacin against Pseudomonas aeruginosa.
    Prosser BL; Taylor DB; Cleeland R
    Chemotherapy; 1991; 37(2):93-7. PubMed ID: 1903341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.
    Hanberger H
    Scand J Infect Dis Suppl; 1992; 81():1-52. PubMed ID: 1322561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa.
    Heffernan AJ; Sime FB; Naicker S; Andrews K; Ellwood D; Guerra-Valero Y; Wallis S; Lipman J; Grimwood K; Roberts JA
    Diagn Microbiol Infect Dis; 2021 Jun; 100(2):115329. PubMed ID: 33714790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
    Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
    Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients.
    Borbolla JR; López-Hernández MA; González-Avante M; DeDiego J; Trueba E; Alvarado ML; Jiménez RM
    Chemotherapy; 2001; 47(5):381-4. PubMed ID: 11561142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bactericidal activity of 6 antibiotics and 3 combinations against 6 strains of Salmonella isolated from blood].
    Chevalier B; Cavallo JD; Meyran M
    Pathol Biol (Paris); 1995 Apr; 43(4):264-9. PubMed ID: 7567112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
    Canis F; Cavallo JD; Husson MO
    Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single daily dosing of amikacin in an in-vitro model.
    Dudley MN; Zinner SH
    J Antimicrob Chemother; 1991 May; 27 Suppl C():15-9. PubMed ID: 1906862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
    McGrath BJ; Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1931-7. PubMed ID: 8239608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
    J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci.
    Roussel-Delvallez M; Wallet F; Barbiery P; Courcol RJ
    J Chemother; 1997 Feb; 9(1):5-8. PubMed ID: 9106011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.